Dr. Hans Loibner has retired as of July 15, 2018 as chief executive officer of APEIRON Biologics AG. Peter Llewellyn-Davies, chief financial officer and chief business officer of APEIRON, has  been appointed chief executive officer. Dr. Loibner will continue to support APEIRON in an advisory capacity. Dr. Loibner had a long and distinguished career at the company, including the establishment, successful development and strategic orientation following its foundation by the well-known Austrian ...